Maria Navarro-Riquelme

Maria Navarro-Riquelme

Auto-generated profile, based on publicly available information

Maria Navarro-Riquelme

Mitochondrial and Neuromuscular Research Group ‘12 de Octubre’ Instituto de Investigación Hospital Universitario 12 de Octubre (imas12) Madrid Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2026 in Neurology Genetics
Verified
Journal Article
Open access
LBLaura Bermejo-Guerrero
Laura Bermejo-Guerrero
JRJuan Luis Restrepo-Vera
Juan Luis Restrepo-Vera
PMPaloma Martin-Jimenez
Paloma Martin-Jimenez
MNMaria Navarro-Riquelme
Maria Navarro-Riquelme
RGRocio Garrido-Moraga
Rocio Garrido-Moraga
CDCristina Domínguez-González
Cristina Domínguez-González
POLG-related disorders exhibit marked phenotypic heterogeneity and frequent clinical overlap, often leading to delayed diagnosis. A precise delineation of their clinical spectrum, natural history, and the identification of reliable biomarkers is essential to improve diagnostic accuracy and guide therapeutic development. We analyzed a cohort of 34 patients with confirmed pathogenic POLG variants, assessing clinical phenotypes, molecular findings, and biomarkers (plasma growth differentiation factor-15 [GDF15] in 16, plasma neurofilament light chain [NF-L] in 14, and mitochondrial DNA [mtDNA] copy number in muscle in 16). Thirty four patients (0.6–71 years) from 33 families were included. Juvenile/adult onset (12–40 years) was the most common presentation (62%). The predominant phenotypic categories were ataxia-neuropathy spectrum ([ANS], 44%), autosomal recessive PEO-plus (arPEO-plus, 26%), and autosomal dominant PEO-plus ([adPEO-plus], 15%), with frequent phenotypic overlap. Recessive inheritance accounted for 74% of cases, with the most common variants being p.([Thr251Ile; Pro587Leu]) paired on 1 allele, p.(Ala467Thr), and p.(Trp748Ser). Dominant variants were associated with milder, primarily myopathic phenotypes. The most common dominant variant was p.(Tyr955Cys). No clear genotype-phenotype correlations were identified among recessive variants. Compared with previously reported cohorts, our patients exhibited a lower prevalence of seizures, hepatopathy, and stroke-like episodes. GDF15 was elevated in 87.5% of patients, with a mean level of 3,315 pg/mL (±1,559.79), showing no significant differences between myopathic and ANS phenotypes, supporting its role as a general biomarker of mitochondrial dysfunction. NF-L was elevated in 78.6% of tested individuals but did not correlate with phenotype or clinical severity (as per Newcastle Mitochondrial Disease Adult Scale score). On average, muscle mtDNA copy number in patients was 76% of that observed in controls, with no differences by phenotype or inheritance pattern. All but 1 patient exhibited multiple mtDNA deletions, likely representing the primary mechanism of oxidative phosphorylation dysfunction rather than mtDNA depletion. POLG-related disorders demonstrate extensive clinical variability with no consistent genotype-phenotype correlation. GDF15 and NF-L may serve as useful, though nonspecific, biomarkers of mitochondrial and neuroaxonal dysfunction, respectively. Prospective studies incorporating advanced molecular profiling are essential to establish reliable outcome measures and inform future therapeutic strategies.

15 September 2026 in Journal of Cachexia, Sarcopenia and Muscle
Verified
Journal Article
Open access
PDF file
ABAna Bermejo‐Moriñigo
Ana Bermejo‐Moriñigo
PMPaloma Martín‐Jiménez
Paloma Martín‐Jiménez
VGVioleta González‐Méndez
Violeta González‐Méndez
LBLaura Bermejo-Guerrero
Laura Bermejo-Guerrero
LOLuz Edith Ochoa-Sánchez
Luz Edith Ochoa-Sánchez
CDCristina Domínguez-González
Cristina Domínguez-González
Background: Quantitative muscle MRI is increasingly used to assess structural muscle damage in inherited myopathies, but its application in primary mitochondrial myopathies (PMM) has not been systematically evaluated in large cohorts. Because PMM are clinically and genetically heterogeneous, objective imaging biomarkers are needed to quantify skeletal‐muscle involvement and define meaningful subgroups. We assessed whether MRI‐derived proton density fat fraction (PDFF) captures genotype‐ and phenotype‐specific patterns of fatty replacement and reflects disease severity using motor function outcomes and circulating biomarkers. Methods: We performed a cross‐sectional analysis of 49 adults with genetically confirmed PMM enrolled in a prospective natural history study. Participants underwent standardised lower‐limb MRI, including T1‐weighted sequences and mDIXON‐QUANT fat fraction imaging. Muscle involvement was assessed semi‐quantitatively with the modified Mercuri scale and quantitatively by PDFF measurement in selected pelvic girdle and thigh muscles. A total fat fraction score (FF sum) was calculated. PDFF was compared across genotypes and phenotypes and against MRC score, NSAA, 6‐min walk test, 100‐m run test, CK, serum creatinine, GDF15 and disease duration. Results: Mean age at onset was 26.3 ± 15.1 years, mean age at MRI was 50.0 ± 12.3 years, and median disease duration was 23 years (IQR 15–31). Genetic diagnoses included mtDNA variants in 29 patients (59.1%; single large‐scale deletions, n = 19; point mutations, n = 10), nuclear variants in POLG ( n = 8), TK2 ( n = 8) and TWNK ( n = 4). Phenotypes were exercise intolerance without overt weakness ( n = 7), isolated progressive external ophthalmoplegia (PEO; n = 16), PEO‐plus ( n = 16) and progressive myopathy ( n = 8). Highest median PDFF values were observed in tensor fasciae latae (31%), gluteus maximus (30%), sartorius (25%) and gracilis (20%). FF sum correlated with MRC score ( r = −0.567, p < 0.0001), NSAA ( r = −0.731, p < 0.0001), 100‐m run test time ( r = 0.629, p < 0.0001), 6‐min walk distance ( r = −0.311, p = 0.0476) and serum creatinine ( r = −0.715, p < 0.0001), but not with CK or GDF15. TK2 deficiency showed the highest fat replacement, particularly in gluteus maximus and gracilis ( p < 0.001). Progressive myopathy showed greater fatty replacement than other phenotypes ( p < 0.001), while exercise intolerance showed higher fat fraction than isolated PEO ( p = 0.033). Conclusions: Quantitative muscle MRI provides objective and clinically meaningful measures of muscle involvement in PMM. MRI‐derived fat fraction reflects disease severity, discriminates between genotypes and phenotypes, and detects subclinical muscle damage. These cross‐sectional findings support PDFF as a candidate imaging biomarker for patient stratification and disease characterisation; prospective longitudinal studies will be required to establish its sensitivity to change and its validity as an outcome measure for therapeutic trials.